Biogen Stock Jumps on Analyst Upgrade, Positive Alzheimer's Drug News

Biogen (NASDAQ: BIIB) shares rallied almost 4.8% in afternoon trading on Monday, defying a broad market downturn after a significant analyst upgrade and encouraging clinical data for its Alzheimer's disease franchise created a cluster of positive catalysts for the biotech firm.

Analyst Upgrade Cites Pipeline Confidence

The primary driver for the stock's outperformance was an upgrade from Truist Securities, which raised its rating on Biogen to Buy from Hold. The firm also increased its price target on the shares to $235 from a previous $190, citing growing conviction in the company's Alzheimer's and immunology pipelines.

The timing of the upgrade provided an immediate catalyst, coming just one day before a scheduled presentation of Phase 2 data for diranersen (BIIB080), Biogen's anti-tau Alzheimer's candidate, at the Alzheimer’s Association International Conference (AAIC).

Leqembi Data Boosts Commercial Outlook

The positive sentiment was reinforced by new data presented by Biogen and its partner Eisai at the AAIC. The data showed that a once-weekly subcutaneous (under-the-skin) autoinjector version of their approved Alzheimer's drug, Leqembi, achieved bioequivalence to the current intravenous formulation.

Ad

This development is significant as a more convenient, at-home administration route could substantially broaden Leqembi's commercial appeal. Other analysts reacted more cautiously, with Wedbush raising its price target while maintaining a Neutral rating, reflecting a Wall Street consensus that remains divided but is showing signs of improvement.

Defying a Market Downturn

Biogen's advance was particularly notable as it occurred against a challenging macroeconomic backdrop. The stock's session high of $210.17 came as major indices were in retreat ahead of key inflation data and the start of earnings season.

On the day, the S&P 500 fell 0.8% and the tech-heavy NASDAQ Composite dropped 1.5% as investors positioned for the June Consumer Price Index report. Biogen's ability to buck the negative trend underscored the strength of its company-specific news flow.